Joint Transnational Call (2026) – Personalised Medicine for CARdiovascular, MEtabolic and kidNey diseases (CARMEN2026)
The following countries (27) are participating in the preparation of the call: Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal, Romania, Slovak Republic, South Africa, Spain, Sweden, The Netherlands and Turkiye. Four of the participating countries are represented by their specific regions (9): Flanders (Belgium), Wallonia-Brussels Federation (Belgium), Lombardy (Italy), Tuscany (Italy), Azores (Portugal), Centro Region (Portugal), Andalusia (Spain), Catalonia (Spain) and Navarre (Spain).
The JTC2026 will fund research projects in human health on innovative PM strategies for patients with cardiovascular, metabolic or kidney diseases. Research projects may focus on a single disease or explore these conditions in combination.
Proposals should address one or more of the following aspects:
- Development and validation of innovative personalised therapeutic approaches for cardiovascular, metabolic or kidney diseases through testing in relevant pre-clinical models (e.g., human cell cultures, organoids, organs-on-chips, disease-specific animal models, or in silico models).
- Identification and validation of molecular markers/signatures or cutting-edge technologies to monitor treatment response in patients with cardiovascular, metabolic or kidney diseases in order to tailor treatment pathways. This may include the analysis of the treatment effectiveness or treatment-related (including multi-medication) adverse effects as well as dose optimisation.
- Identification and validation of stratifying molecular markers/signatures or stratifying diagnostic technologies for early disease risk prediction and prevention of dis-ease worsening or comorbidities in patients with cardiovascular, metabolic or kidney diseases, thereby delaying the progression to cardiovascular-kidney-metabolic syndrome. While clinical studies (exploratory/proof-of-concept/early stage clinical studies or sub-studies) can be funded in this call, larger clinical trials are out of scope.
While clinical studies (exploratory/ proof-of-concept/ early-stage or sub-studies) may be funded under this call, larger clinical trials are beyond its scope. Proposed clinical studies must be feasible and capable of being completed within the timeframe and budget of this call.
Only transnational projects will be funded.
ANR will only fund the French partners of the selected projects. In agreement with ANR policy, funded researchers should respect the guidelines of the Nagoya protocol and consider open access publication of their results.
The call will be implemented in two stages, i.e. a pre- and a full proposal phase.
The eligibility criteria and rules regarding the consortium composition are outlined in the Call Text.
The Call Text, Guidelines for Applicants, and the Application Form are available on the JTC2026 webpage.
The completed scientific application must be submitted on the electronic proposal submission tool PT-Outline (no proposals will be accepted by ANR directly). ANR does not require any additional documents at the time of submission.
The EP PerMed Joint Call Secretariat (JCS):
The French National Research Agency
Monika Frenzel
Phone: +33 01 73 54 83 32
Email: eppermed(at)agencerecherche.fr
Consult the upcoming and current calls of the appelsprojetsrecherche.fr portal
The appelsprojetsrecherche.fr portal centralises all information on calls for proposals and calls for applications from ADEME, ANR, Inserm including ANRS, Anses and INCa. It provides a simplified access to upcoming and ongoing calls, giving a greater visibility to funding opportunities. Following their closing date, the calls remain published for a few months.
Portail appelsprojetsrecherche.fr
